-+ 0.00%
-+ 0.00%
-+ 0.00%

Verastem Oncology Expects $17.5M In Q4 2025 Revenues For AVMAPKI FAKZYNJA CO-PACK, Up From $12.5M In Q4 2024, While Advancing VS-7375 Development In 2026

Benzinga·02/04/2026 12:34:52
Listen to the news
  • Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million for the full year 2025, following U.S. FDA approval in May 20251
  • Company plans to continue rapidly advancing clinical development program for VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in several advanced KRAS G12D solid tumor indications
  • Company sees preliminary unaudited cash, cash equivalents, and investments of $205 million as of December 31, 2025; pro-forma year-end cash, cash equivalents and investments of $234 million inclusive of net proceeds from exercise of expiring cash warrants; expected cash runway into first half of 2027
  • Leadership to participate in a fireside chat at the Guggenheim Emerging Outlook Conference in New York City on February 11, 2026